Where the Patient Cannot Consent and the Trial Still Has to Run.
Regulatory strategy for the ICU — where sepsis has defeated forty trials and the endpoint is twenty-eight-day mortality.
The ICU Is the Only Place Where Research Runs Without Permission.
A patient in septic shock or cardiac arrest cannot consent, has no time for a surrogate to be found, and needs the intervention in minutes. Regulation's answer is exception from informed consent — a narrow provision requiring community consultation, public disclosure, an independent monitor, and a life-threatening situation with no satisfactory alternative. It is the most ethically loaded machinery in clinical research.
It is also slow, public, and easy to get wrong: the community consultation is a genuine engagement obligation, not a press release. We build EFIC programs that hold up to the scrutiny they invite, because a trial that mishandles consent is not a trial with a protocol problem — it is a trial that should not have enrolled anyone.
Community consultation, public disclosure, an independent monitor. EFIC is machinery, and it is slow by design.
Sepsis Is Medicine's Most Expensive Unsolved Regulatory Problem.
More than forty phase 3 sepsis trials have failed. The pharmacology was often plausible; the trial design was the recurring defect — and each failure taught the same lesson.
A syndrome, not a disease
The population is the problemSepsis is a clinical definition covering wildly different biology — infection source, organism, host response, and organ trajectory all vary. Enrolling all of it dilutes any real effect to nothing.
28-day mortality
An endpoint that hides benefitThe conventional primary is binary, late, and dominated by competing causes of death. A drug can meaningfully help organ function and still not move it.
Timing is everything
Hours, not daysThe therapeutic window may be measured in hours from onset, while enrolment machinery takes longer — so the drug is often given after the biology it targets has moved on.
Enrichment is the answer
Biology, not consensus criteriaPredictive enrichment on biomarkers or host-response phenotypes narrows the population to patients who can respond — and is where the field's credible hope now sits.
The FDA is not the obstacle here. The agency has been consistently open to enrichment strategies, adaptive designs, and alternative endpoints in sepsis; what it will not accept is a broad syndromic population and a hope that mortality moves. The programs worth funding define a biologically coherent population first and let the endpoint follow from it.
Critical Care Regulates Drugs, Machines, and Algorithms Together.
The ICU is device-dense, drug-dense, and increasingly algorithm-dense — and the sickest patients in the building are the test population for all of it.
Sepsis & Septic Shock
Where forty failed trials made predictive enrichment and biologically coherent populations the only credible path.
Respiratory Failure
Ventilators, ECMO, and the drugs that have never beaten lung-protective ventilation — a field where the standard of care is very hard to improve.
Monitoring & Devices
Continuous monitoring, closed-loop systems, and the alarm-fatigue and human-factors questions the FDA now treats as safety issues.
Clinical Decision Support
Sepsis prediction algorithms — where the CDS exemption's boundaries, real-world performance, and alert burden all get tested at once.
Acute Kidney Injury
Continuous renal replacement in the ICU, and a drug field with no approved therapy and no accepted trial design.
Pandemic Readiness
EUAs, pre-EUA packages, and the hard lesson that authorisation is not approval and the data still has to arrive.
EUA moves a product to the bedside in weeks. The confirmatory data still has to arrive — now, and in public.
Emergency Use Authorisation Is Not a Shortcut. It Is a Debt.
COVID-19 ran the largest live experiment in emergency regulation ever conducted. EUAs moved products to bedsides in weeks on a may-be-effective standard — and then revocations, narrowed indications, and the collapse of several high-profile authorisations demonstrated what the standard actually meant. Authorisation was a loan against evidence, and the evidence came due.
The durable lesson for critical care sponsors is that an EUA obligates you to the confirmatory program you would have run anyway, on a harder schedule and in public. We plan emergency pathways with the full approval already designed behind them, because the authorisation is the easy part.
Everything That Makes the ICU Urgent Makes It Hard to Study.
Unconscious patients, hours-long windows, competing mortality, and a syndrome definition instead of a disease.
phase 3 sepsis trials have failed. Almost none failed for lack of a plausible mechanism — they failed on population and endpoint.
Exception from informed consent requires community consultation, public disclosure, and an independent monitor. It is slow, and it is the only way.
Mortality remains the conventional primary endpoint — binary, late, and capable of hiding a genuine benefit entirely.
Six Failure Modes We Are Brought In to Prevent.
The ICU punishes optimism about populations more than any other setting.
The syndrome as a population
Enrolling consensus-criteria sepsis without enrichment, and diluting a real effect in a biologically incoherent cohort.
EFIC underestimated
Treating community consultation as a formality, and meeting an IRB — or a journalist — who does not agree.
Mortality as the only endpoint
Building a program around 28-day mortality when the drug's benefit is organ function, and having nothing to show for it.
Enrolment window missed
A protocol whose screening and randomisation machinery takes longer than the therapeutic window it is aiming at.
EUA without a confirmatory plan
Taking emergency authorisation with no funded, enrolling confirmatory trial, then facing revocation in public.
CDS exemption misread
Assuming a sepsis prediction algorithm falls outside device regulation when its output and automation bias put it squarely inside.
Critical Care Regulatory Leadership for the Hardest Setting in Medicine.
Our critical care leads have designed enriched sepsis programs, run EFIC trials through community consultation, and taken ICU devices and EUAs through the agency.
"Sepsis has not failed for lack of good molecules. It has failed because we kept enrolling a definition instead of a disease. Fix the population and the endpoint stops being impossible."
The discipline we bring across sepsis, respiratory failure, ICU devices, and emergency pathways.
Planning an ICU Trial? Define the Population Before the Endpoint.
Bring senior critical care regulatory leadership in while enrichment, consent, and the endpoint are still design decisions.
Senior-led. Embedded in your team. No junior hand-offs.